19 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
good partial response (VGPR) or better, as determined by an independent review committee.Median duration of response (DoR) of 29
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
REGN
4 Jun 24
arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
REGN
4 Jun 24
. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships
i7t4c
CRL
IQV
MAIA
31 May 24
. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com
k7zkas88qg77w 9rskt3env
REGN
17 May 24
, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam
8zoeek56rlzd2jmgfyym12nz2vm2jlyg21
REGN
3 May 24
antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi
n024qk
REGN
2 May 24
, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing
7w0k8h3mkvsjihqzrvxahdks xd76dnh8gdbw0ndnay8k7fd1mfqsa
REGN
30 Apr 24
in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has
w94tgi8q
REGN
18 Apr 24
arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier
vv9wxb7 filfv3bsy201yo7owe7v079vjh
REGN
12 Apr 24
antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including
9nnbdrbqp272g24llfqg532n6sauw 73a1y1i5tgv9es
REGN
11 Apr 24
, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing
j8phyl lnrhu7z056jcmnjt
REGN
8 Apr 24
a complete response (CR) or better and 62% achieving a very good partial response (VGPR) or better, as determined by an independent review
escso6s3z959ebpj328wr8w9o4gi4tmrr395v9wmivrln w52f
REGN
7 Apr 24
by an independent review committee.1-month median time to response (range: <1-6 months). In responders, the median time to a VGPR
13gnv934oxyc70gipjj0ni9irr18dp
REGN
28 Mar 24
. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage
6dz3qgh3i 9pmaykv30ijwz2kpv4u44f3z44cf91dx2cejhj4fx
ARGX
ATNM
MRNA
28 Mar 24
is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com
jpjuriqy4fqa2ajr
REGN
26 Mar 24
and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology
vwizplh1a46x4qhaypmhia9gxupcx83ivyr1dh1twg4
ARGX
ATNM
AZN
26 Mar 24
, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative
- Prev
- 1
- Next